GO
Loading...

Enter multiple symbols separated by commas

Dyax Says Genetic Disease Drug Meets Goals; Shares Surge

Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.

The drug, codenamed DX-88, achieved statistically significant results for both the primary and secondary endpoints, Dyax said in a statement.

Hereditary angioedema is characterized by episodes of acute swelling and inflammation.

The company said the overall safety results showed that the drug continues to be well tolerated.

Dyax said it will present more detailed results next week.

Shares of the company rose to $5.87 in late electronic trading, after closing at $4.00 Thursday on the Nasdaq.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Amgen's Q2 beat

    Amgen is reporting EPS beat of $2.57 adjusted on revenue beat of $5.37 billion, with CNBC's Meg Tirrell.

  • Gartman: 2015 rate hike unlikely

    CNBC's Steve Liesman and Dennis Gartman of the Gartman Letter discuss current economic conditions and whether the Fed may still raise rates this year.

  • What's going on with oil?

    Peter Costa of Empire Executions tracks oil and the market's action into the close.